Xifyrm is a drug owned by Azurity Pharmaceuticals Inc. It is protected by 1 US drug patent filed in 2025 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Jul 31, 2041. Details of Xifyrm's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US12263176 | Pharmaceutical liquid compositions of meloxicam |
Jul, 2041
(15 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease
the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that drug.
Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in the
patent process of
the drug which can give an idea of how early a drug's generic could be available. The next section
provides a list of
recent legal activities on Xifyrm's patents.
Latest Legal Activities on Xifyrm's Patents
Given below is the list of recent legal activities going on the following patents of Xifyrm.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Patent eCofC Notification | 08 Jul, 2025 | US12263176 |
| Mail Patent eCofC Notification | 08 Jul, 2025 | US12263176 |
| Recordation of Patent eCertificate of Correction | 08 Jul, 2025 | US12263176 |
| Email Notification | 08 Jul, 2025 | US12263176 |
| Post Issue Communication - Certificate of Correction | 18 Jun, 2025 | US12263176 |
| Mail Patent eGrant Notification | 01 Apr, 2025 | US12263176 |
| Email Notification | 01 Apr, 2025 | US12263176 |
| Recordation of Patent eGrant | 01 Apr, 2025 | US12263176 |
| Patent Issue Date Used in PTA Calculation | 01 Apr, 2025 | US12263176 |
| Patent eGrant Notification | 01 Apr, 2025 | US12263176 |
US patents provide insights into the exclusivity only within the United States, but
Xifyrm is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Xifyrm's family patents as well as insights into
ongoing legal events
on those patents.
Xifyrm's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Xifyrm's generic launch date based on the expiry of its last outstanding patent is estimated to be Jul 31, 2041 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Xifyrm Generic API suppliers:
Meloxicam is the generic name for the brand Xifyrm. 24 different companies have already filed for the generic of Xifyrm, with Novitium Pharma having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Xifyrm's generic
Alternative Brands for Xifyrm
There are several other brand drugs using the same active ingredient (Meloxicam) as Xifyrm. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |
|---|---|---|
| Avondale Pharms |
| |
| Axsome |
| |
| Baudax |
| |
| Heron Theraps Inc |
| |
| Iceutica Operations |
| |
| Nanjing Delova |
| |
| Tersera |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Meloxicam, Xifyrm's active ingredient. Check the complete list of approved generic manufacturers for Xifyrm
About Xifyrm
Xifyrm is a drug owned by Azurity Pharmaceuticals Inc. Xifyrm uses Meloxicam as an active ingredient. Xifyrm was launched by Azurity in 2025.
Approval Date:
Xifyrm was approved by FDA for market use on 05 June, 2025.
Active Ingredient:
Xifyrm uses Meloxicam as the active ingredient. Check out other Drugs and Companies using Meloxicam ingredient
Dosage:
Xifyrm is available in solution form for intravenous use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 30MG/ML (30MG/ML) | SOLUTION | Prescription | INTRAVENOUS |